The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
D | Dermatologicals | |
2
|
D05 | Antipsoriatics | |
3
|
D05B | Antipsoriatics for systemic use | |
4
|
D05BB | Retinoids for treatment of psoriasis |
| Code | Title | |
|---|---|---|
| D05BB01 | Etretinate | |
| D05BB02 | Acitretin |
| Active Ingredient |
|---|
|
Acitretin, a synthetic aromatic derivative of retinoic acid, has a favourable therapeutic ratio, with a greater and more specific inhibitory effect on psoriasis and disorders of epithelial keratinisation. The usual therapeutic response to acitretin consists of desquamation (with or without erythema) followed by more normal re-epithelialisation. Acitretin is the main active metabolite of etretinate. |
|
|
| Document | Type | Information Source | |
|---|---|---|---|
| SORIATANE Capsule | MPI, US: SPL/Old | FDA, National Drug Code (US) |